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Abstract
Background: Alzheimer disease (AD) is characterized by the accumulation of beta-amyloid (Aβ) plaques and
neurofibrillary tangles composed of hyperphosphorylated tau, which together lead to neurodegeneration and
cognitive decline. Current therapeutic approaches have primarily aimed to reduce pathological aggregates of either
Aβ or tau, yet phase 3 clinical trials of these approaches have thus far failed to delay disease progression in
humans. Strong preclinical evidence indicates that these two abnormally aggregated proteins interact synergistically
to drive downstream neurodegeneration. Therefore, combinatorial therapies that concurrently target both Aβ and
tau might be needed for effective disease modification.
Methods: A combinatorial vaccination approach was designed to concurrently target both Aβ and tau pathologies.
Tau22/5xFAD (T5x) bigenic mice that develop both pathological Aβ and tau aggregates were injected
intramuscularly with a mixture of two MultiTEP epitope vaccines: AV-1959R and AV-1980R, targeting Aβ and tau,
respectively, and formulated in AdvaxCpG, a potent polysaccharide adjuvant. Antibody responses of vaccinated
animals were measured by ELISA, and neuropathological changes were determined in brain homogenates of
vaccinated and control mice using ELISA and Meso Scale Discovery (MSD) multiplex assays.
Results: T5x mice immunized with a mixture of Aβ- and tau-targeting vaccines generated high Aβ- and tau-specific
antibody titers that recognized senile plaques and neurofibrillary tangles/neuropil threads in human AD brain
sections. Production of these antibodies in turn led to significant reductions in the levels of soluble and insoluble
total tau, and hyperphosphorylated tau as well as insoluble Aβ42, within the brains of bigenic T5x mice.
Conclusions: AV-1959R and AV-1980R formulated with AdvaxCpG adjuvant are immunogenic and therapeutically
potent vaccines that in combination can effectively reduce both of the hallmark pathologies of AD in bigenic mice.
Taken together, these findings warrant further development of this vaccine technology for ultimate testing in
human AD.
Keywords: MultiTEP platform, Alzheimer’s disease, Protein epitope vaccine, Antibody, Adjuvant, Bigenic mice, T5x
mice, Aβ42 and tau pathology
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Background
Alzheimer’s disease (AD) is a complex and multifactorial
disease involving genetic and environmental risk factors
that together lead to the progressive accumulation of
two hallmark pathologies: β-amyloid plaques and neuro-
fibrillary tangles (NFTs). Although many clinical trials
have aimed to reduce β-amyloid and, more recently, to
target the accumulation of tau that drives NFT forma-
tion, debate remains regarding which of these patholo-
gies represents the most tractable target, and the precise
timing for these potential treatments. Recent longitu-
dinal analyses of participants within the Alzheimer’s Dis-
ease Neuroimaging Initiative (ADNI) demonstrated
evidence of synergism between Aβ and phosphorylated
tau (p-tau) suggesting these pathologies may interact to
trigger the progression from amnestic mild cognitive im-
pairment (MCI) subjects to AD dementia [1, 2]. PET im-
aging studies suggest that Aβ deposits start decades
before dementia onset, and may or may not precede tau
pathology, with the latter correlating better with symp-
tom onset and the degree of dementia [3, 4]. According
to the modified amyloid cascade model proposed by Jack
et al. [5–7], primary age-related tauopathy (PART) de-
velops universally as a function of aging and, by itself,
produces no or only mild cognitive symptoms. Aβ de-
position occurs independently in the neocortex and in-
duces or facilitates the spread of pathological tau,
perhaps by promoting the production of pathological tau
strains [8]. Pathological tau is directly associated with
neurodegeneration, which in turn drives cognitive de-
cline. In this model of AD, Aβ does not directly cause
cognitive symptoms but is still central to disease patho-
genesis as a dominant driver of downstream pathological
processes including tau pathology [6, 7]. Indeed, a recent
study utilizing serial PET measurements of both amyloid
and tau provides strong additional support for this hy-
pothesis [9].
This synergistic model suggests that combinatorial/
multi-target therapies directed at the accumulation of
both amyloid and tau pathologies may be more effective
in the treatment of AD than previously tested unimodal
approaches.
Recently, we demonstrated that the combination of
AV-1959R and AV-1980R vaccines targeting Aβ and tau,
respectively, induced robust antibody responses against
various forms of both Aβ and tau pathological molecules
in wildtype mice [10]. Both of these vaccines are based
on the MultiTEP platform that consists of a string of 12
non-self, pathogen-derived T helper (Th) epitopes to
which Aβ B cell epitopes (AV-1959R) and tau B cell epi-
topes (AV-1980R) are attached. A dual vaccine express-
ing both Aβ and tau B cell epitopes (AV-1953R)
generated similar concentrations of anti-Aβ antibodies,
but significantly lower concentrations of anti-tau
antibodies compared to mice vaccinated with a combin-
ation of AV-1959R and AV-1980R [10], suggesting a
mixed vaccine approach may be preferred.
Here, we tested the therapeutic efficacy of co-
formulated vaccines targeting Aβ and tau administered
simultaneously in combination with AdvaxCpG adjuvant
in the Tau22/5xFAD (T5x) mouse model of AD. T5x
bigenic mice [11] were generated by crossing two exist-
ing and well-characterized transgenic models, 5xFAD
[12] and THY-Tau22 [13], and were previously shown to
develop highly aggressive Aβ and tau pathology, and
thus likely represent a useful model for testing potential
AD therapies. The bigenic T5x mice exhibit an approxi-
mately threefold increase in misfolded and hyperpho-
sphorylated tau over the parental Tau22 strain, further
supporting the hypothesis that Aβ accelerates tau
pathology [11].
Materials and methods
Mice
Thy-Tau22-5xFAD (T5x) double transgenic AD mice
were generated as described in [11]. Briefly, Thy-Tau22
mice express human 4 repeat tau with two frontotem-
poral dementia-associated point mutations (G272V and
P301S) under control of the neuronal driven promoter
Thy1.2 and are maintained on a C57Bl6/J background
[13]. The 5xFAD mice used in this study are also main-
tained on a congenic C57Bl6/J and co-expresses human
amyloid precursor protein (APP695) carrying the Swed-
ish, Florida, and London mutations and a human
presenilin-1 (PS1) transgene carrying the M146L and
L286V mutations under the Thy-1 promoter. Both APP
and PS1 transgenes are co-integrated and thus co-
inherited. Heterozygous Thy-Tau22 and 5xFAD mice
were crossed to create Thy-Tau22-5xFAD (T5x) mice
that were genotyped via PCR amplification of human
tau, PS1, and APP transgenes. Both female and male ani-
mals were used in this study and sex-dependent effects
examined. All animals were housed in a temperature
and light cycle-controlled facility, and their care was
under the guidelines of the National Institutes of Health
and an approved IACUC protocol at University of Cali-
fornia, Irvine.
Epitope vaccines and purification of proteins
To prepare two recombinant proteins, minigenes
encoding 3Aβ1–11-MultiTEP or 3Tau2–18-MultiTEP were
cloned into the modified Escherichia coli expression
vector pET11 (for AV-1959R; Novagen, MA) or pET24a
(for AV-1980R; Novagen, MA) in frame with 6xHis-Tag
at the C-terminus. Gene encoding 2N4R tau protein was
amplified from human whole brain Marathon®-Ready
cDNA library (Clontech) using primers 5′-catatggct-
gagccccgccaggagttcgaagtgatg (forward) and 5′-
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ctcgagtcacaaaccctgcttggccagggaggcagac (reverse) and
cloned into the pET24a + E. coli expression vector in
frame with 6xHis-tag at the C-terminus using restriction
sites NdeI and XhoI. DNA sequencing was performed to
confirm that the generated plasmids contained the cor-
rect sequences. Recombinant proteins were purified
from E. coli BL21 (DE3) cells transformed with pET11/
3Aβ1–11-MultiTEP, pET24a/3Tau2–18-MultiTEP, or
pET24a/Tau plasmids as described [10, 14, 15] for epi-
tope vaccines and in [16] for Tau protein. The final re-
combinant protein was analyzed in 10% Bis-Tris gel
electrophoresis (NuPAGE Novex Gel, Invitrogen, CA).
Protein bands were visualized by Coomassie dye, and
specificity of the bands was confirmed by Western blot
(WB) using 6E10 and anti-tau2–18 1C9 monoclonal anti-
bodies [10]. The level of endotoxin was measured using
E-TOXATE kits, as recommended by the manufacturer
(Sigma, St Louis, MO).
Preparation of oligomeric recombinant tau
Oligomeric forms of tau protein were prepared as de-
scribed by Combs et al. [17]. Briefly, arachidonic acid in
ethanol was added to recombinant tau protein in
polymerization buffer (5mM DTT, 100mM NaCl,
100 μM EDTA, and 10mM HEPES at pH 7.64) to a final
concentration of 75 μM in order to induce tau
polymerization. The reaction was allowed to proceed
overnight, and the extent of aggregation was confirmed by
western blotting. The aggregated tau sample was aliquoted
and was stored at − 80 °C until used in SPR assay.
Experimental protocols
Three groups of T5x mice were immunized with AV-1959R
(20 μg/per mouse/per injection), AV-1980R (20 μg/per
mouse/per injection), or a mixture of AV-1959R and AV-
1980R proteins (20 μg protein/mouse/injection), all formu-
lated with AdvaxCpG adjuvant (Vaxine Pty Ltd., Adelaide
Australia) at 1mg/mouse/injection. Control groups of T5x
mice were injected with AdvaxCpG adjuvant only or PBS. All
mice were injected four times intramuscularly. Sera were
collected 14 days after third immunizations, and anti-Aβ
and anti-tau antibody responses were analyzed. At age of
8 months old, mice were terminated and brains were col-
lected for biochemical and immunohistological analysis.
More detailed experimental protocols are provided in Fig. 1.
Detection of Aβ- and tau-specific antibodies
The concentrations of anti-Aβ and anti-tau antibodies in
serum were determined by ELISA, as described previ-
ously [15, 18, 19]. To measure anti-Aβ and anti-tau anti-
body concentration, plates were coated with 1 μg/per
well Aβ42 peptide (American Peptide, CA), tau2–18 pep-
tide (GenScript, NJ), or full-length recombinant tau pro-
tein (purified at The Institute for Molecular Medicine,
Huntington Beach, CA), respectively. Anti-Aβ and anti-
tau antibody concentrations were calculated using a cali-
bration curve generated with affinity-purified polyclonal
Fig. 1 Design of immunization study of T5x mice. Experimental protocol in T5x mice vaccinated with AV-1959R and AV-1980R proteins separately
or mixed together formulated in AdvaxCpG adjuvant. Control mice were injected either with PBS or AdvaxCpG adjuvant only
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antibodies from sera of mice vaccinated with AV-1959R/
A and AV-1980R/A, respectively. HRP-conjugated anti-
mouse IgG (Jackson ImmunoResearch Laboratories, ME)
was used as secondary antibody.
Epitope mapping of tau-specific antibodies
Epitope mapping of anti-tau antibodies was performed
by “alanine scanning” using competitive ELISA. Briefly,
17 peptides spanning tau2–18 sequence, but possessing
one alanine substitution in each position were synthe-
sized. Ninety-six-well plates (Immulux HB; Dynex Tech-
nologies, Inc., VA) were coated with 1 μg/well (in 100 μl;
Carbonate-Bicarbonate buffer, pH 9.6, o/n at 4 °C) tau2–
18 peptide (GenScript, NJ). Next day coated plates were
blocked with blocking buffer (3% dry, non-fat milk in
TBST, 300 μl/well). Serial dilutions of reference wild
type (tau2–18) or mutated test peptides (corresponding to
0.02 μM, 0.1 μM, 0.5 μM, 2.5 μM, 5 μM, 12.5 μM, and
25 μM final concentrations) were incubated with im-
mune sera diluted 1: 300,000 (corresponding to the lin-
ear region of the curve for binding to Tau2–18 peptide)
for 1.5 h at 37 °C. After incubation, 100 μl of antibody/
peptide mixture was added into the wells. HRP-
conjugated goat anti-mouse IgG (1:2500; Jackson Immu-
noResearch Laboratories, PA) were used as secondary
antibodies. The reaction was developed by adding 3,3′,5,
5′tetramethylbenzidine (TMB) (Pierce, IL) substrate so-
lution and stopped with 2M H2SO4. The optical density
(OD) was read at 450 nm (Biotek, Synergy HT, VT). The
percent of binding of sera blocked with wild type or mu-
tated peptides to tau2–18 was calculated relative to the
binding of sera without competing peptides to tau2–18 as
100%. The half maximal inhibitory concentration (IC50)
for each peptide was calculated.
Surface plasmon resonance (SPR)
Binding studies were performed at 25 °C using a Biacore
2000 optical biosensor equipped with a Protein A-coated
sensor chip and equilibrated with running buffer (10
mM HEPES, 150 mM NaCl, 0.01% Tween-20, 0.1 mg/
mL BSA, pH 7.4). The surfaces were regenerated with
two 12-s injections of 150 mM phosphoric acid after
each binding cycle.
Antibody captures for kinetic analysis of antigen bind-
ing. For each binding cycle, the antibodies were diluted
into running buffer and injected across individual Pro-
tein A surfaces. These injections produced capture levels
of ~ 55–75 RU (resonance units). Using a short-and-
long injection approach, tau monomer and oligomer
were tested in triplicate in a threefold dilution series
starting at 40 nM (this concentration was established
using an estimated average molecular weight of 138 kDa
for the oligomer). For each tau/antibody interaction, the
responses from the three runs were globally fitted to a 1:
1 interaction model (shown as the overlaid smooth red
lines in the figures) to obtain the binding parameters
listed in the table in Fig. 4.
Detection of Aβ plaques and tau tangles in human brain
tissues by IHC and confocal microscopy
Sera from mice immunized with AV-1959R/A, AV-
1980R/A, and mixture of AV-1959R/A and AV-1980R/
A, as well as control mice injected with AdvaxCpG only,
were screened for the ability to bind to human Aβ pla-
ques or/and tau tangles using 40-μm brain sections of
formalin-fixed cortical tissues from a severe AD case (re-
ceived from Brain Bank and Tissue Repository, MIND,
UC Irvine) using immunohistochemistry, as described
previously [20–22]. In addition, brain sections were
stained with anti-Aβ (beta-amyloid (1–42), 1:250, Invi-
trogen, CA) and humanized anti-tau (Armanezumab, 1:
1000; Institute for Molecular Medicine, CA) antibody as
positive controls. Sections were imaged using an Olym-
pus FX1200 confocal microscope, with identical laser
and detection settings across a given immunolabel.
Mouse brain tissue preparation, immunohistochemistry,
and confocal microscopy
Following perfusion, one hemisphere from each mouse
was postfixed in 4% paraformaldehyde for 48 h then
stored in PBS + 0.05% sodium azide. Fixed half-brains
were placed in 30% sucrose for at least 48 h before being
cut in the coronal plane (40-μm sections) using a freez-
ing sliding microtome. Brain sections were rinsed in PBS
before blocking in PBS + 0.05% Triton-X with 10% goat
serum for 1 h. First, samples were stained with Amylo-
Glo™ RTD Amyloid Plaque Stain Reagent (Biosensis,
Australia) for 15 min, washed three times, and then in-
cubated in pS199 (Abcam, UK, 1:1000) and PHF-1 (gift
from Dr. Peter Davis, 1:1000) phospho-tau primary anti-
bodies at 4 °C overnight. The next day, sections were
washed three times with PBS and placed in appropriate
Alexa Fluor-conjugated secondary antibody solutions at
room temperature for 1 h. Sections were rinsed three
additional times, mounted onto slides, and coverslipped
using Fluoromount-G. For confocal microscopy, im-
munofluorescent staining was performed on equivalent
brain sections and imaged on the Olympus FX1200 con-
focal microscope. Tau tangles and β-amyloid plaques
were visualized using Z-stack maximum-projection im-
ages taken through the entire depth of the section at 1-
μm intervals.
Biochemical analyses
Right hemispheres, previously frozen on dry ice and
stored at − 80 °C, were crushed on dry ice using mortar
and pestle, then homogenized in solution of T-PER
(Thermo Scientific, Waltham, MA) and phosphatase and
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protease inhibitor mixtures (Thermo Scientific, MA and
Roche, CA) and processed as previously described [22–24].
Quantitative biochemical analysis of human Aβ was con-
ducted using commercially available electrochemilumines-
cent multiplex assay system [Meso Scale Discovery (MSD)].
Human Aβ triplex (6E10 capture antibody) was used for
simultaneous measurement of Aβ38, Aβ40, and Aβ42 in
both soluble and insoluble protein fractions [24].
Concentrations of human total and phosphorylated
tau in samples (soluble and insoluble brain extracts)
were determined by Tau (total) Human ELISA kit, Tau
[pS396] Human ELISA Kit, Tau [pS199] Human ELISA
Kit, Tau [pT181] Human ELISA Kit, and Tau [pT231]
Human ELISA Kit (all from ThermoFisher Scientific,
MA), according to the manufacturer’s instructions.
Soluble SDS-PAGE WB and quantifaction was per-
formed following standard protocols as previously de-
scribed [22–24]. Primary antibodies used for WB
analysis included the following: Armanezumab (1:2000;
Institute for Molecular Medicine, Huntington Beach,
CA), anti-GFAP (1:500; Millipore-Sigma, MO), anti-
P2RY12 (1:500; Millipore-Sigma, MO), and anti-CD45
(1:500; Bio-Rad, CA). All blot membranes were also la-
beled with anti-β-actin antibodies (1:1000; Millipore-
Sigma, MO) as a loading control.
Statistical analysis
All statistical parameters [mean, standard deviation
(SD), significant difference, etc.] used in experiments
were calculated using Prism 6 software (GraphPad Soft-
ware, Inc.). Statistically significant differences were ex-
amined using unpaired t test or one-way ANOVA with
Tukey’s multiple comparisons test (p value < 0.05 was
considered as statistically different).
Results
Immunogenicity of vaccines in T5x mice
We previously found that a MultiTEP vaccine carrying
both Aβ and tau epitopes together within a single pro-
tein, AV-1953R, induced significantly lower titers of
anti-tau antibodies in wildtype mice compared with
combined delivery of two separate anti-Aβ, AV-1959R,
and anti-tau, AV-1980R vaccines [10]. Therefore, to test
the efficacy of combination therapy, we instead here
used a mixture of two vaccines: (1) AV-1959R carrying
three copies of Aβ B cell epitope (Aβ1–11) attached to
MultiTEP and (2) AV-1980R, carrying three copies of
tau N-terminal epitope (tau2–18) attached to MultiTEP,
formulated in AdvaxCpG adjuvant (AV-1959R/A + AV-
1980R/A). Two-month-old T5x bigenic mice were im-
munized with the mixture of both vaccines or with each
vaccine separately (Fig. 1). Mice in all groups generated
high titers of antibodies specific to Aβ42 and/or tau2–18
(Fig. 2, Additional file 1: Figure S1). The humoral
response in all groups was high, ranging from 55 to
4785 μg/ml; however, the average concentrations of anti-
Aβ (Fig. 2a) antibodies were significantly lower in mice
immunized with the AV-1959R/A + AV-1980R/A com-
bination compared to mice vaccinated with AV-1959R/
A vaccine alone. Similar, but non-significant trend was
observed in mice immunized with AV-1980R/A com-
pared with combination vaccines (Fig. 2b). In addition,
the antibodies obtained bound equally well in ELISA to
both the tau2–18 peptide and the full-length recombinant
tau protein (Fig. 2b, c). As expected, these vaccines were
specific, so immunization with AV-1980R/A alone did
not generate anti-Aβ antibodies and immunization with
AV-1959R/A alone did not induce production of anti-
tau antibodies (Fig. 2).
Previously, we mapped the epitope for monoclonal
antibody generated after immunization of mice with
AV-1980R/A [16]. Here, we also mapped the epitopes
recognized by antibodies induced in mice vaccinated
with AV-1980R/A using alanine scanning. The data
demonstrated that in bigenic mice, AV-1980R/A active
vaccination generated antibodies specific to two overlap-
ping epitopes comprising amino acids 4–8 (PRQEFE)
and 7–13 (EFEVMED) of the N-terminus of human tau
(Fig. 3a). The binding avidity of anti-Aβ11 polyclonal
antibodies generated by AV-1959R/A vaccination in
mice [25], rabbits [26], and monkeys [14] to different
forms of Aβ42 (monomeric, oligomeric, and fibrillar) was
previously demonstrated. Thus, in this study, we sought to
measure the binding avidity of anti-tau polyclonal anti-
bodies purified from sera of AV-1980R/A vaccinated T5x
mice to monomeric and oligomeric forms of recombinant
Tau (2N4R) protein. As shown in Fig. 3b, immobilized
anti-tau antibodies bound to tau monomers and oligomers
with high avidity (KD= 31.5pM for monomers and 23.7pM
for oligomers), indicating a marginally higher avidity of the
antibodies for tau oligomers than monomers.
Next, we examined whether the immune mouse sera
could recognize human senile plaques and tau-laden
neurofibrillary tangles, by performing immunofluores-
cent staining of brain sections of AD case. As expected,
sera from T5x mice immunized with AV-1959R/A
bound only to amyloid plaque pathology. Conversely,
sera from AV-1980R/A-vaccinated mice bound to tau
tangles (NFT) and neuritic threads, but not amyloid pla-
ques. Importantly, immune sera from mice vaccinated
with the combined vaccines labeled both hallmark path-
ologies: amyloid plaques and neurofibrillary tangles
(Fig. 4). The specific binding of sera (green) to amyloid
plaques (blue) and/or NFTs and neuritic threads (red)
was further demonstrated by co-labeling brain sections
with anti-Aβ42 Ab, a marker of beta-amyloid, and hu-
manized Armanezumab mAb that is specific to the N-
terminal epitope of Tau. Importantly, no binding of AD
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brains was observed with sera from control mice
injected with AdvaxCpG adjuvant only. Thus, combin-
ation therapy with the mixture of MultiTEP-platform-
based vaccines can elicit a strong epitope-specific anti-
body response targeting simultaneously both of the mis-
folded proteins involved in AD pathology.
Changes in Aβ and tau pathology in the brains of T5x
mice immunized with single or dual vaccines
Previously, we showed that bigenic T5x mice exhibit ac-
celerated tau pathology compared with the parental THY-
Tau22 strain and reduced insoluble Aβ42 compared with
parental 5XFAD mice [11]. We analyzed changes in both
soluble and insoluble forms of these proteins in brain
homogenates from vaccinated mice using sensitive ELISAs
for total tau and tau phosphorylated at positions pS199,
pT231, pS396, and pT181 and by Meso Scale Discovery
(MSD) analysis of Aβ42, Aβ40, and Aβ38.
Using this approach, we detected a significant reduction
in both soluble and insoluble levels of Aβ42 in mice immu-
nized with AV-1959R/A (Fig. 5a, d). Mice immunized with
a combination vaccine showed a significant reduction of in-
soluble Aβ42 (Fig. 5d). However, when these cohorts were
analyzed by gender, we observed a significant reduction of
soluble Aβ42 in female mice received mixed vaccine, but
not AV-1959R/A alone (Additional file 1: Figure S2a), while
male mice showed significant reduction of soluble Aβ42 in
AV-1959R/A cohort and only a slight trend of reduction in
Fig. 2 MultiTEP-based vaccines induced high titers of anti-Aβ and anti-tau antibodies in T5x mice. Concentration of antibodies binding to Aβ42
(a), tau2–18 peptide (b), and full-length recombinant tau protein (c) was detected in sera of male and female mice by ELISA. Lines represent the
average value for combined male and female mice (***p≤ 0.001). Of note, mice immunized with AV-1959R/A did not induce antibodies specific
to tau, while vaccination of mice with AV1980R/A did not generate ant-Aβ antibodies
Fig. 3 a Epitope mapping of immune sera was performed by alanine scanning competition ELISA. Two overlapped epitopes have been detected
comprising amino acids 4–9 PRQEFE and amino acids 7–13 EFEVMED. Percent of inhibition of antibody binding to Tau2–18 peptide with mutated
peptides (alanine substitution of each single amino acid) is shown in the table. b Binding avidity of anti-tau2–18 antibodies generated in T5x mice
was determined by surface plasmon resonance (SPR). Monomeric and oligomeric forms of recombinant human tau (2N4R) were passed through
antibodies immobilized on a Protein A-coated sensor chip
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AV-1959R/1980R/A cohort (Additional file 1: Figure S3a),
thus making this difference non-significant when combined
female/male groups were compared (Fig. 5a). In contrast,
insoluble amyloid-β was significantly reduced in male mice
(Additional file 1: Figure S3d) and showed a well-
pronounced downward trend in femalemice (Additional file 1:
Figure S2d). These data may reflect the sex-dependent im-
pact of antibodies on Aβ pathology. A non-significant trend
towards decreased Aβ40 (Fig. 5b, e) and Aβ38 (Fig. 5c, f) was
also observed in mice immunized with AV-1959R/A.
Significant reductions in total and phosphorylated sol-
uble tau were seen in mice treated with the tau vaccine
AV-1980R/A as well as mice treated with the vaccine
combination, AV-1959R/A + AV-1980R/A (Fig. 6a–e).
Interestingly, we also detected significant reductions of
several phosphorylated species of tau in mice immunized
with the β-amyloid vaccine, AV-1959R/A, alone
(Fig. 6a–c; Additional file 1: Figures S4 and S5), indicat-
ing that decreases in Aβ42 also led to a decrease of tau
pathology, consistent with previous reports in the 3xTg-
AD mouse model [27]. The pattern of reduced species
of soluble Tau was slightly different in female and male
mice immunized with either anti-Aβ or anti-Tau
vaccines alone or in combination (Additional file 1: Fig-
ures S4 and S5). These differences could be associated
with differences in the pathological burden of Aβ and
Tau in mice of different genders as well as the titers of
induced antibodies. Female mice have higher levels of
Aβ42, but lower levels of Tau than male mice. Additional
studies that employ greater numbers of both male and
female mice will be needed to fully characterize the po-
tential differential changes that occur between male and
female immunized T5x mice. Regardless of these intri-
guing sex-dependent differences, the reduction of all an-
alyzed soluble tau species in the combined gender
groups demonstrates the robust effect on multiple tau
species achieved by this approach.
Analysis of insoluble species of Aβ and Tau also re-
vealed sex-dependent effects of vaccination. Although
vaccinated female mice showed a downward trend in
both Aβ42 and tau molecules, a significant reduction
was observed only in male mice (Additional file 1:
Figure S4f-g; Figure S5f-j) leading to significant
decrease in the combined male and female groups for
all detected insoluble tau species (Fig. 6f–j and
Additional file 1: Figure S4e).
Fig. 4 AV-1959R/A and AV-1980R/A immune sera (both separately and mixture), but not AdvaxCpG injected (control) sera bound to the 50-μm
brain sections of cortical tissues from an AD case, female 89 years old, Plaque stage-C, Tangle stage-6. Brain sections were stained with anti-Aβ
(beta-amyloid (1–42), 1:250) and humanized anti-tau (Armanezumab, 1:1000) antibody as positive controls (scale = 20 μm)
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To determine whether immunization might lead to
changes in microgliosis and astrocytosis, we performed
WB with antibodies specific to GFAP, P2RY12, and
CD45 (Additional file 1: Figure S6). Somewhat suprisingly,
no differences were detected in the expression of the astro-
cytic activation marker GFAP, the microglial homoeostatic
marker P2RY12, or the myeloid activation marker CD45,
between control and vaccinated T5x mice. These data sug-
gest that although antibody-mediated reduction in path-
ology can be expected to decrease glial activation, beta-
amyloid and tau antibodies may alternatively offset any
such response by activating microglia via Fc-mediated sig-
naling. Thus, these potentially apposing effects might result
in no significant changes in glial activation.
As ELISA measurements provide a more quantitative
approach than histology, we used ELISA to measure sol-
uble and insoluble Aβ, tau, and phospho-tau species to
determine the effectiveness of the AV-1959R/A, AV-
1980R/A, and combined vaccination approach. However,
we also asked whether an immunohistochemical and
confocal microscopy approach might provide a further
indication of altered pathology. Sections from 3 mice per
group were examined using double-labeling for PHF-1
and pS199 tau along with Amylo-Glo, a Thioflavin S
analog that labels the beta-pleated sheet confirmation of
amyloid plaques. Confocal Z-stacks were captured, with
representative images (Additional file 1: Figure S7) indi-
cating that AV-1959R/A vaccination or the combined
AV-1959R/A + AV-1980R/A approach successfully re-
duced both Aβ and tau pathology. In contrast, vaccin-
ation with AV-1980R/A alone reduced Tau pathology
but not Aβ plaques, as would be expected from the bio-
chemical data detailed above (Fig. 5).
Discussion
Despite some encouraging clinical data for BAN2401
monoclonal antibody (mAb), which selectively binds
large soluble Aβ protofibrils [28], the vast majority of Aβ
therapeutics trials, including but not limited to active
and passive vaccines, have thus far failed to modify
Fig. 5 Effect of protein vaccination on Aβ proteins in T5x mice. Level of human Aβ42 (a, d), Aβ40 (b, e), and Aβ38 (c, f) peptides in brain soluble
(a–c) and insoluble (d–f) extractions were analyzed by MSD assay. Lines represent average (*p≤ 0.05; **p≤ 0.01)
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cognition in MCI and AD subjects [29–31]. The failure of
these trials may reflect treatment being initiated too late in
the pathological process when neuronal damage or other
downstream pathologies cannot be reversed. Therefore,
thinking has moved to the idea that Aβ-based mono treat-
ment should be initiated as a preventive rather than a
therapeutic measure. Such a long-term prophylactic strat-
egy could likely only be practically achieved in terms of
both compliance and affordability, through the use of a safe
and immunogenic vaccine rather than monoclonal anti-
body infusions [28, 30, 32–38]. Nevertheless, based on the
recently published data indicating that Aβ and tau aggre-
gates interact synergistically to drive downstream neurode-
generation [1, 2, 9, 39, 40], we hypothesize that vaccines
targeting both pathological molecules simultaneously might
be the most effective therapeutic approach [10].
The current study tested the immunogenicity of AV-
1959R/A and AV-1980R/A as a combined vaccine in the
T5x bigenic mouse model of AD which exhibits robust
accumulation of intraneuronal tau and extensive extra-
cellular amyloid plaque pathology within the hippocam-
pus, neocortex, and amygdala by 7 months of age [11].
By comparison with wildtype mice [10], humoral im-
mune responses in bigenic mice vaccinated either with
AV-1959R/A or with AV-1980R/A alone were higher
than in mice vaccinated with combined vaccines (Fig. 2
and Additional file 1: Figure S1). Notably, combined
vaccines formulated in AdvaxCpG adjuvant successfully
generated high concentrations (55 to 4785 μg/ml) of
antibodies specific to both Aβ and tau (Fig. 2 and
Additional file 1: Figure S1). These milligram levels of
antibodies in the sera of vaccinated animals are due to
the MultiTEP vaccine platform that strongly activates T
helper cells in mice of H-2b immune haplotype [10, 41].
Importantly, this universal MultiTEP vaccine platform is
designed to provide a broad coverage of human MHC
class II polymorphism by utilizing a wide array of tet-
anus toxin, hepatitis B, and influenza Th epitopes
Fig. 6 Effect of protein vaccination on tau proteins in T5x mice. Level of human total tau protein (a, f) and several phosphorylated tau species
(b–e and g–j) in brain soluble (a–e) and insoluble (f–j) extractions were analyzed by ELISA. Lines represent average (*p≤ 0.05; **p≤ 0.01;
***p≤ 0.001; ****p≤ 0.0001)
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incorporated into the MultiTEP platform [26]. These
foreign Th epitopes incorporated into the MultiTEP
platform are very immunogenic in mice of different hap-
lotypes, in rabbits, and in monkeys with highly poly-
morphic MHC class II genes [14, 22, 26, 41, 42]. A
growing amount of evidence suggests that prophylactic
vaccination delivered prior to clinical symptoms may be
needed to prevent the development of AD fully. However,
therapeutic treatments that target amyloid and tau path-
ology and alleviate key symptoms and/or slow the pro-
gression of AD are still desperately needed to treat the
millions of people currently affected by AD. Yet, it is well
known that older people respond poorly to new vaccines
due to immunosenescence, characterized by an abundance
of memory T cells and a decrease in the number of naive
T cells with age [43]. The MultiTEP strategy provides a
unique opportunity to generate high levels of antibodies
in the elderly by activating not only naïve Th cells, but
also pre-existing memory Th cells previously generated in
response to infections and/or vaccinations with tetanus
toxin, hepatitis B, and influenza, thereby overcoming
immunosenescence. Indeed, the feasibility of this strategy
based on pre-existing memory Th cells was previously
demonstrated [10, 21, 44].
Earlier, we demonstrated that in mice and monkeys,
AV-1959 induced antibodies specific to the AEFRH epi-
tope of Aβ1–11 peptide incorporated in this vaccine [41].
This immunodominant B cell epitope of N-terminus of
Aβ42 [45] is widely used in preclinical and clinical stud-
ies, and data from various groups, including us, suggest
that high-affinity antibodies specific to this region re-
duce AD-like pathology not only in mouse models of
AD but also in brains of vaccinated people [18, 20, 21,
25, 44, 46–51]. Immunizations with AV-1959R/A also
induced therapeutically potent antibodies that signifi-
cantly reduced soluble and insoluble Aβ42 pathology in
this pathologically aggressive bigenic mouse model of
AD (Fig. 5).
Here, we also mapped the immunogenic B cell epi-
topes of tau2–18 and demonstrated that antibodies in-
duced by AV-1980R/A recognized two overlapping
epitopes comprising 4–8 aa and 7–13 aa (Fig. 3). The
later epitope coincides with that of the TNT1 mAb,
which is shown to recognize pre-tangle pathology in
early Braak stages and more compact classical neurofib-
rillary tangles, but not late-stage ghost tangles [17]. We
previously compared the binding of Armanezumab,
mAb specific to aa 4–8, with TNT1 and showed that,
under denaturing conditions, both antibodies bind to tau
protein in AD, but not in non-AD brains. However,
under denaturing conditions, Armanezumab recognizes
tau aggregates with a higher molecular weight compared
to TNT1 [16]. Thus, we believe that AV-1980R/A, which
induces antibodies specific to two B cell epitopes, might
be therapeutically more effective than the mAb. In fact,
in the stringent T5x bigenic mouse model of AD used
here, AV-1980R/A vaccine has induced high-affinity
antibodies (Fig. 3) that significantly decreased soluble
and insoluble total and various phosphorylated tau spe-
cies in the brains of vaccinated animals (Fig. 6).
We expected that neuropathological changes in the
brains of mice immunized with a combination vaccine
would be more pronounced compared to single vacci-
nated mice, but the reduction in Aβ42 and various tau
species was comparable in mice immunized with either
a single or a combination vaccine. Perhaps this can be
explained by data showing that the combined vaccine
generated lower titers of anti-Aβ and anti-tau antibodies
in mice than single vaccines (Fig. 2). Nevertheless, we
anticipate that a simultaneous reduction of both patho-
logical molecules may lead to a better improvement in
cognitive functions, although future studies will need to
carefully test this question in appropriate mouse models.
Such behavioral studies may need to be tested in a less ag-
gressive mouse model that better reflects the more com-
mon, sporadic form of Alzheimer’s disease in which the
time window for effective prevention and treatment is
likely wider, e.g., APP knock-in mice crossbred with hu-
manized Tau knock-in mice [52–57]. As cognitive deficits
tend to develop at later ages in knock-in models, these
mice likely represent models of preclinical AD that could
be well suited for testing preventative active vaccines.
Interestingly, we observed a significant decrease of tau
in mice immunized with a single vaccine targeting Aβ,
AV-1959R/A (Fig. 6), but did not see decreased Aβ42 in
mice immunized with single anti-tau vaccine, AV-1980R/
A (Fig. 5). This data, as well as pervious data showing a
threefold increase in misfolded and hyperphosphorylated
tau in mice generated by crossing of Thy-Tau22 with
5xFAD mice [11] further, supports the hypothesis that Aβ
can accelerate and exacerbate tau pathology.
Conclusions
Here, we showed that combined active vaccine based on
the MultiTEP platform and formulated with AdvaxCpG
adjuvant, which has been shown to be safe and effective
in human trials [58–61], is highly immunogenic in
bigenic mice exhibiting both Aβ and tau pathologies.
Generated antibodies specifically recognize Aβ plaques,
neurofibrillary tangles, and neuritic threads in human
AD tissue, and most importantly, vaccination leads to
significant decreases in multiple soluble and insoluble
tau species and insoluble Aβ42 in the brains of trans-
genic mice. This data suggests that a combined vaccin-
ation approach could potentially be used to induce
strong immune responses against both of the hallmark
pathologies of AD in a broad population of vaccinated
subjects with high MHC class II gene polymorphisms.
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Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13195-019-0556-2.
Additional file 1: Figure S1. Humoral immune responses in female
and male T5x mice vaccinated with different vaccines. Concentration of
antibodies binding to Aβ42 (a, d), tau2-18 peptide (b, e) and full-length
recombinant tau protein (c, f) were detected in sera by ELISA. Lines repre-
sent average. Statistically significant differences were examined using un-
paired t-test (**p ≤ 0.01; Control group - n=8 for female and n=14 for
male; AV-1959R/A group - n=6 for female and n=8 for male, AV-1980R/A
group - n=6 for female and n=8 for male and AV-1959R/A+AV-1980RA
group - n=5 for female and n=7 for male). Figure S2. Effect of protein
vaccination on Aβ proteins in female, T5x mice. Level of human Aβ42 (a
and d), Aβ40 (b and e) and Aβ38 (c and f) peptides in brain soluble (a-c)
and insoluble (d-f) extractions were analyzed by MSD assay. Error bars
represent average ± SEM. Statistically significance were calculated against
Control group using ANOVA test (*p ≤ 0.01; Control group - n=8 for fe-
male and n=14 for male; AV-1959R/A group - n=6 for female and n=8 for
male, AV-1980R/A group - n=6 for female and n=8 for male and AV-
1959R/A+AV-1980RA group - n=5 for female and n=7 for male). Figure
S3. Effect of protein vaccination on Aβ proteins in male, T5x mice. Level
of human Aβ42 (a and d), Aβ40 (b and e) and Aβ38 (c and f) peptides in
brain soluble (a-c) and insoluble (d-f) extractions were analyzed by MSD
assay. Error bars represent average ± SEM. Statistically significance were
calculated against Control group using ANOVA test (*p ≤ 0.05; ***p ≤
0.001; Control group - n=8 for female and n=14 for male; AV-1959R/A
group - n=6 for female and n=8 for male, AV-1980R/A group - n=6 for fe-
male and n=8 for male and AV-1959R/A+AV-1980RA group - n=5 for fe-
male and n=7 for male). Figure S4. Effect of protein vaccination on tau
proteins in female, T5x mice. Level of human total tau protein (a, f) and
several phosphorylated tau species (b-e and g-j) in brain soluble (a-e) and
insoluble (fj) extractions were analyzed by ELISA. Error bars represent
average ± SEM. Statistically significance were calculated against Control
group using ANOVA test (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤
0.0001; Control group - n=8 for female and n=14 for male; AV-1959R/A
group - n=6 for female and n=8 for male, AV-1980R/A group - n=6 for fe-
male and n=8 for male and AV-1959R/A+AV-1980RA group - n=5 for fe-
male and n=7 for male). Figure S5. Effect of protein vaccination on tau
proteins in male, T5x mice. Level of human total tau protein (a, f) and
several phosphorylated tau species (b-e and g-j) in brain soluble (a-e) and
insoluble (fj) extractions were analyzed by ELISA. Error bars represent
average ± SEM. Statistically significance were calculated against Control
group using ANOVA test (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤
0.0001; Control group - n=8 for female and n=14 for male; AV-1959R/A
group - n=6 for female and n=8 for male, AV-1980R/A group - n=6 for fe-
male and n=8 for male and AV-1959R/A+AV-1980RA group - n=5 for fe-
male and n=7 for male). Figure S6. Vaccination with protein vaccines did
not change astrogliosis and microgliosis in brains of T5x mice. The levels
of GFAP, P2RY12 and CD45 proteins in the soluble fraction of the brain
extracts were analyzed by Western blotting and quantitatively deter-
mined by densitometric analysis with normalization against β-actin. The
relative protein level in the brains of vaccinated mice is presented as a
percentage of the protein level in the brains of control mice. Error bars
represent average ± SEM. Statistically significant differences were exam-
ined using one-way ANOVA (n = 12 for Control group and n=11 for all
vaccinated groups). Figure S7. Reduced β-amyloid and tau pathology in
T5x mice following vaccination with different proteins. Representative
pictures of brain CA1 region immunostained for Amylo-GloTM (ThS, anti-
Aβ) and pS199 and PHF-1 (anti-tau) antibodies. Scale: 60μm (lowpwr) and
15μm (highpwr).
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